Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.10.2012 | Preclinical Study

Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production

verfasst von: Zhi Shi, Wei-Min Yang, Li-Pai Chen, Dong-Hua Yang, Qi Zhou, Jin Zhu, Jun-Jiang Chen, Ruo-Chun Huang, Zhe-Sheng Chen, Ruo-Pan Huang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Drug resistance remains a major hurdle to successful cancer treatment. Many mechanisms such as overexpression of multidrug-resistance related proteins, increased drug metabolism, decreased apoptosis, and impairment of signal transduction pathway can contribute multidrug resistance (MDR). Recent studies strongly suggest a close link between cytokines and drug resistance. To identify new targets involved in drug resistance, we established a multidrug-resistant human breast cancer cell line MCF-7/R and examined the cytokine profile using cytokine antibody array technology. Among 120 cytokines/chemokines screened, IL-6, IL-8, and 13 other proteins were found to be markedly increased in drug-resistant MCF-7/R cell line as compared to sensitive MCF-7/S cell line, while 7 proteins were specifically reduced in drug-resistant MCF-7/R cells. Neutralizing antibodies against IL-6 and IL-8 partially reversed the drug resistance of MCF-7/R to paclitaxel and doxorubicin, while a neutralizing antibody against MCP-1 had no significant effect. Inhibition of endogenous IL-6 or IL-8 by siRNA technology significantly enhanced drug sensitivity of MCF-7/R cells. Furthermore, overexpression of IL-6 or IL-8 expression by transfection increased the ADM resistance in MCF-7/S cells. Our data suggest that increased expression levels of IL-6 and IL-8 may contribute to MDR in human breast cancer cells.
Literatur
2.
Zurück zum Zitat Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1(2):93–105PubMedCrossRef Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1(2):93–105PubMedCrossRef
3.
Zurück zum Zitat Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12(4):570–594PubMedCrossRef Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12(4):570–594PubMedCrossRef
5.
Zurück zum Zitat Baraldi-Junkins CA, Beck AC, Rothstein G (2000) Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 14(1):45–61 viiiPubMedCrossRef Baraldi-Junkins CA, Beck AC, Rothstein G (2000) Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 14(1):45–61 viiiPubMedCrossRef
6.
Zurück zum Zitat Balkwill FR (1994) Cytokine therapy of cancer. The importance of knowing the context. Eur Cytokine Netw 5(4):379–385PubMed Balkwill FR (1994) Cytokine therapy of cancer. The importance of knowing the context. Eur Cytokine Netw 5(4):379–385PubMed
8.
Zurück zum Zitat Foti E, Ferrandina G, Martucci R, Romanini ME, Benedetti Panici P, Testa U, Mancuso S, Scambia G (1999) IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels. Oncology 57(3):211–215PubMedCrossRef Foti E, Ferrandina G, Martucci R, Romanini ME, Benedetti Panici P, Testa U, Mancuso S, Scambia G (1999) IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels. Oncology 57(3):211–215PubMedCrossRef
9.
Zurück zum Zitat Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA (1994) Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73(7):1882–1888PubMedCrossRef Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA (1994) Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73(7):1882–1888PubMedCrossRef
10.
Zurück zum Zitat Negus RP, Balkwill FR (1996) Cytokines in tumour growth, migration and metastasis. World J Urol 14(3):157–165PubMedCrossRef Negus RP, Balkwill FR (1996) Cytokines in tumour growth, migration and metastasis. World J Urol 14(3):157–165PubMedCrossRef
11.
Zurück zum Zitat Fasciani A, D’Ambrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR (2001) Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 75(6):1218–1221PubMedCrossRef Fasciani A, D’Ambrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR (2001) Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 75(6):1218–1221PubMedCrossRef
12.
Zurück zum Zitat Hassan MI, Kassim SK, Saeda L, Laban M, Khalifa A (1999) Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue. Anticancer Res 19(6C):5657–5662PubMed Hassan MI, Kassim SK, Saeda L, Laban M, Khalifa A (1999) Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue. Anticancer Res 19(6C):5657–5662PubMed
13.
Zurück zum Zitat Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5(11):3445–3453PubMed Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5(11):3445–3453PubMed
14.
Zurück zum Zitat Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10(1):33–41PubMedCrossRef Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10(1):33–41PubMedCrossRef
15.
Zurück zum Zitat Bamberger ES, Perrett CW (2002) Angiogenesis in epithelian ovarian cancer. Mol Pathol 55(6):348–359PubMedCrossRef Bamberger ES, Perrett CW (2002) Angiogenesis in epithelian ovarian cancer. Mol Pathol 55(6):348–359PubMedCrossRef
16.
Zurück zum Zitat Sieczkiewicz GJ, Hussain M, Kohn EC (2002) Angiogenesis and metastasis. Cancer Treat Res 107:353–381PubMed Sieczkiewicz GJ, Hussain M, Kohn EC (2002) Angiogenesis and metastasis. Cancer Treat Res 107:353–381PubMed
17.
Zurück zum Zitat Huang R, Lin Y, Wang CC, Gano J, Lin B, Shi Q, Boynton A, Burke J, Huang RP (2002) Connexin 43 suppresses human glioblastoma cell growth by down-regulation of monocyte chemotactic protein 1, as discovered using protein array technology. Cancer Res 62(10):2806–2812PubMed Huang R, Lin Y, Wang CC, Gano J, Lin B, Shi Q, Boynton A, Burke J, Huang RP (2002) Connexin 43 suppresses human glioblastoma cell growth by down-regulation of monocyte chemotactic protein 1, as discovered using protein array technology. Cancer Res 62(10):2806–2812PubMed
18.
Zurück zum Zitat Huang RP (2001) Detection of multiple proteins in an antibody-based protein microarray system. J Immunol Methods 255(1–2):1–13PubMedCrossRef Huang RP (2001) Detection of multiple proteins in an antibody-based protein microarray system. J Immunol Methods 255(1–2):1–13PubMedCrossRef
19.
Zurück zum Zitat Huang RP (2003) Cytokine antibody arrays: a promising tool to identify molecular targets for drug discovery. Comb Chem High Throughput Screen 6(8):769–775PubMed Huang RP (2003) Cytokine antibody arrays: a promising tool to identify molecular targets for drug discovery. Comb Chem High Throughput Screen 6(8):769–775PubMed
20.
Zurück zum Zitat Huang RP, Huang R, Fan Y, Lin Y (2001) Simultaneous detection of multiple cytokines from conditioned media and patient’s sera by an antibody-based protein array system. Anal Biochem 294(1):55–62. doi:10.1006/abio.2001.5156 PubMedCrossRef Huang RP, Huang R, Fan Y, Lin Y (2001) Simultaneous detection of multiple cytokines from conditioned media and patient’s sera by an antibody-based protein array system. Anal Biochem 294(1):55–62. doi:10.​1006/​abio.​2001.​5156 PubMedCrossRef
22.
Zurück zum Zitat Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, Huang RP (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109(4):507–515. doi:10.1002/ijc.11724 PubMedCrossRef Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, Huang RP (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109(4):507–515. doi:10.​1002/​ijc.​11724 PubMedCrossRef
23.
Zurück zum Zitat Lin Y, Huang R, Santanam N, Liu YG, Parthasarathy S, Huang RP (2002) Profiling of human cytokines in healthy individuals with vitamin E supplementation by antibody array. Cancer Lett 187(1–2):17–24PubMedCrossRef Lin Y, Huang R, Santanam N, Liu YG, Parthasarathy S, Huang RP (2002) Profiling of human cytokines in healthy individuals with vitamin E supplementation by antibody array. Cancer Lett 187(1–2):17–24PubMedCrossRef
24.
Zurück zum Zitat Wanichkul T, Han S, Huang RP, Sidell N (2003) Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril 79(Suppl 1):763–769PubMedCrossRef Wanichkul T, Han S, Huang RP, Sidell N (2003) Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril 79(Suppl 1):763–769PubMedCrossRef
27.
Zurück zum Zitat Huang RP, Liu C, Fan Y, Mercola D, Adamson ED (1995) Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 55(21):5054–5062PubMed Huang RP, Liu C, Fan Y, Mercola D, Adamson ED (1995) Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res 55(21):5054–5062PubMed
28.
Zurück zum Zitat Huang RP, Fan Y, deBelle I, Ni Z, Matheny W, Adamson ED (1998) Egr-1 inhibits apoptosis during the UV response: correlation of cell survival with Egr-1 phosphorylation. Cell Death Differ 5(1):96–106. doi:10.1038/sj.cdd.4400322 PubMedCrossRef Huang RP, Fan Y, deBelle I, Ni Z, Matheny W, Adamson ED (1998) Egr-1 inhibits apoptosis during the UV response: correlation of cell survival with Egr-1 phosphorylation. Cell Death Differ 5(1):96–106. doi:10.​1038/​sj.​cdd.​4400322 PubMedCrossRef
29.
Zurück zum Zitat Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, Akiyama S (1999) Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91(19):1647–1653PubMedCrossRef Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, Akiyama S (1999) Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 91(19):1647–1653PubMedCrossRef
30.
Zurück zum Zitat Zeng H, Bain LJ, Belinsky MG, Kruh GD (1999) Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 59(23):5964–5967PubMed Zeng H, Bain LJ, Belinsky MG, Kruh GD (1999) Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 59(23):5964–5967PubMed
31.
Zurück zum Zitat Huang RP, Fan Y, Hossain MZ, Peng A, Zeng ZL, Boynton AL (1998) Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res 58(22):5089–5096PubMed Huang RP, Fan Y, Hossain MZ, Peng A, Zeng ZL, Boynton AL (1998) Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res 58(22):5089–5096PubMed
32.
Zurück zum Zitat Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103(5):642–646. doi:10.1002/ijc.10833 PubMedCrossRef Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103(5):642–646. doi:10.​1002/​ijc.​10833 PubMedCrossRef
33.
Zurück zum Zitat Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71(2):354–356PubMedCrossRef Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71(2):354–356PubMedCrossRef
34.
Zurück zum Zitat Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61(24):8851–8858PubMed Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61(24):8851–8858PubMed
36.
37.
Zurück zum Zitat Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G, De Maria R (2003) Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63(20):6784–6790PubMed Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesu G, De Maria R (2003) Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63(20):6784–6790PubMed
38.
Zurück zum Zitat Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T (2004) Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res 64(4):1293–1298PubMedCrossRef Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T (2004) Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res 64(4):1293–1298PubMedCrossRef
39.
Zurück zum Zitat Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T et al. (1994) Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263(5143):89–92PubMedCrossRef Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T et al. (1994) Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263(5143):89–92PubMedCrossRef
Metadaten
Titel
Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production
verfasst von
Zhi Shi
Wei-Min Yang
Li-Pai Chen
Dong-Hua Yang
Qi Zhou
Jin Zhu
Jun-Jiang Chen
Ruo-Chun Huang
Zhe-Sheng Chen
Ruo-Pan Huang
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2196-0

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.